Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis "AbbVie delivered another outstanding quarter with strong ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immuno ...

In August, AbbVie launched its new pan-genomic hep C treatment Mavyret, costing $26,400 in the US for an eight week course, a deep undercutting of Epclusa’s list price of $74,760 for a 12 week ...

These four Dividend Aristocrats are Buy-rated sector leaders with yields above 3%. Passive income investors can buy and hold ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.